ASH 2014: Clinical trial provides overall survival data that support autologous stem cell transplantion for HIV-associated lymphoma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Joseph Alvarnas (City of Hope National Medical Center, Duarte, CA) presents data from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) trial, which prospectively evaluated overall survival after autologous haematopoietic stem cell transplantation in patients with chemotherapy-sensitive, relapsed or refractory HIV-associated lymphoma, including diffuse large B-cell lymphoma, plasmablastic lymphoma, Burkitt/Burkitt-like lymphoma and Hodgkin lymphoma.